Related Experiment Video
Updated: Feb 7, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Clinical syndromes associated with mtDNA mutations: where we stand after 30 years
Valerio Carelli1,2, Chiara La Morgia3,2
1IRCCS Institute of Neurological Sciences of Bologna, Bellaria Hospital, Bologna, Italy valerio.carelli@unibo.it.
Abstract:
The landmark year 1988 can be considered as the birthdate of mitochondrial medicine, when the first pathogenic mutations affecting mtDNA were associated with human diseases. Three decades later, the field still expands and we are not 'scraping the bottom of the barrel' yet. Despite the tremendous progress in terms of molecular characterization and genotype/phenotype correlations, for the vast majority of cases we still lack a deep understanding of the pathogenesis, good models to study, and effective therapeutic options. However, recent technological advances including somatic cell reprogramming to induced pluripotent stem cells (iPSCs), organoid technology, and tailored endonucleases provide unprecedented opportunities to fill these gaps, casting hope to soon cure the major primary mitochondrial phenotypes reviewed here. This group of rare diseases represents a key model for tackling the pathogenic mechanisms involving mitochondrial biology relevant to much more common disorders that affect our currently ageing population, such as diabetes and metabolic syndrome, neurodegenerative and inflammatory disorders, and cancer.
Insights
Mitochondrial medicine, born in 1988, studies rare diseases caused by mtDNA mutations. New technologies offer hope for understanding pathogenesis and developing treatments for these and common age-related disorders.
Area of Science:
- Mitochondrial Medicine
- Genetics
- Molecular Biology
Background:
- Mitochondrial medicine emerged in 1988 with the discovery of pathogenic mtDNA mutations linked to human diseases.
- Despite progress in molecular characterization and genotype/phenotype correlations, understanding pathogenesis, developing models, and finding effective therapies remain significant challenges.
Purpose of the Study:
- To review the current state of mitochondrial medicine, highlighting challenges and recent technological advancements.
- To discuss the potential of new technologies in addressing gaps in understanding and treating mitochondrial diseases.
- To emphasize the relevance of mitochondrial rare diseases as models for common age-related disorders.
Main Methods:
- Review of recent technological advancements in mitochondrial disease research.
- Analysis of progress in molecular characterization and genotype/phenotype correlations.
- Exploration of induced pluripotent stem cells (iPSCs), organoid technology, and tailored endonucleases.
Main Results:
- Significant progress has been made in understanding mitochondrial DNA (mtDNA) mutations and their associated diseases.
- New technologies like iPSCs and organoids offer promising avenues for disease modeling and therapeutic development.
- Mitochondrial diseases serve as crucial models for studying common age-related conditions.
Conclusions:
- Despite challenges, recent technological breakthroughs provide unprecedented opportunities to advance mitochondrial medicine.
- There is hope for developing effective therapeutic options for primary mitochondrial diseases.
- Research in mitochondrial disorders informs our understanding of broader health issues like diabetes, neurodegeneration, and cancer.
Related Concept Videos
Mutations
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Viral Mutations
Standing Waves
Modes of Standing Waves - I

